TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00912574
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study: NCT02556268
Drug: ATRIPLA
Normalized name: Atripla
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
Study: NCT02556268
Drug: COMPLERA
Normalized name: Complera
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
Study: NCT02556268
Drug: STRIBILD
Normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
Study: NCT02556268
Drug: TRIUMEQ
Normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
Study: NCT03966326
Drug: sevoflurane and fentanil plus PECS II block
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
Study: NCT00695396
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
Study: NCT00695396
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
Study: NCT02672423
Drug: Abemaciclib Capsules (Reference Formulation)
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02672423
Drug: Abemaciclib Tablet (Test Formulation)
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT01545297
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
Study: NCT01545297
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
Study: NCT03832621
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
Study: NCT03832621
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab 480 mg i.v. every 4 weeks
Study: NCT03832621
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
Study: NCT01312818
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
Study: NCT01312818
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
Study: NCT01312818
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
Study: NCT01312818
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for \>18 years on Days 1-16.
Study: NCT01239771
Drug: TC-5214
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
Study: NCT01698931
Drug: repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period
Study: NCT01698931
Drug: glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
Study: NCT03936361
Drug: Statins
Normalized name: Endostatins
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
Study: NCT02256761
Drug: BIRT 2584 XX - multiple escalating dose
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504439
Drug: SB-656933-AAA
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
Study: NCT00335309
Drug: IV Amoxicillin and Clavulanate acid
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
Study: NCT03752112
Drug: Cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
Study: NCT04803513
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab according to clinical indication in real life
Study: NCT01456130
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin tablets
Study: NCT03023969
Drug: ozone oxygen mixture
Normalized name: ozone
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive 10 ml of ozone oxygen mixture under variable dosing
Study: NCT03302403
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is used for lymphodepletion.
Study: NCT00378638
Drug: bevacizumab combined with dose dense chemotherapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00400517
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: doses up to 400 mg/day
Study: NCT02995512
Drug: Colchicine 0.6 mg tablets
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.2 mg PO followed by 0.6 mg PO 1 hour later
Study: NCT01773967
Drug: micro-crystalline cellulose
Normalized name: micro-crystalline cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule PO bid x 5 days
Study: NCT00618735
Drug: BIIB021
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
Study: NCT00618735
Drug: BIIB021
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT04643847
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
Study: NCT00754689
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tablet, oral administration
Study: NCT00754689
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, oral administration
Study: NCT00235222
Drug: stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02274961
Drug: S-pantoprazole 10mg
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02240121
Drug: Rifaximin EIR
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study: NCT02213068
Drug: belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
Study: NCT02213068
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
Study: NCT02213068
Drug: MPA
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
Study: NCT02389465
Drug: Escitalopram + Placebo
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a placebo in addition to escitalopram.
Study: NCT02852798
Drug: Apatinib Combined With Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
Study: NCT03806530
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsule
Study: NCT03806530
Drug: Ropinirole
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.50 mg capsule
Study: NCT03806530
Drug: Placebo Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT03806530
Drug: Placebo Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo capsule
Study: NCT02563678
Drug: Hyperbaric Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy
Study: NCT02069977
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01393340
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab.
Study: NCT01902342
Drug: Oseltamivir 75 mg 1 cap
Normalized name: oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00859235
Drug: Chlorhexidine gluconate 0.2%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth wash prior to procedure
Study: NCT01897142
Drug: Placebo for PF-05230907
Normalized name: PF-05230907
DrugBank: PF-05230907 (DB18417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT01897142
Drug: Placebo for PF-05230907
Normalized name: PF-05230907
DrugBank: PF-05230907 (DB18417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT01897142
Drug: Placebo for PF-05230907
Normalized name: PF-05230907
DrugBank: PF-05230907 (DB18417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT01897142
Drug: Placebo for PF-05230907
Normalized name: PF-05230907
DrugBank: PF-05230907 (DB18417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT01897142
Drug: Placebo for PF-05230907
Normalized name: PF-05230907
DrugBank: PF-05230907 (DB18417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT01897142
Drug: Placebo for PF-05230907
Normalized name: PF-05230907
DrugBank: PF-05230907 (DB18417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT03149159
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
Study: NCT03149159
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
Study: NCT00730353
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate 37.5 mg orally, daily
Study: NCT00730353
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
Study: NCT00110045
Drug: caspofungin acetate
Normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03971162
Drug: 3+PRN
Normalized name: Hexapeptide 3
DrugBank: Acetyl hexapeptide-3 (DB11709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
Study: NCT03971162
Drug: 6+PRN
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
Study: NCT00645840
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive daily anakinra therapy for 28 days
Study: NCT03502915
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50% nitrous oxide/50% oxygen via Nitronox delivery device
Study: NCT00010075
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00161044
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01280786
Drug: Elesclomol Sodium
Normalized name: Elesclomol
DrugBank: Elesclomol (DB05719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
Study: NCT02217813
Drug: Tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg of current commercial formulation
Study: NCT02217813
Drug: Tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg of new formulation
Study: NCT01340664
Drug: Canagliflozin 50 mg
Normalized name: canagliflozin 50 MG
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
Study: NCT01340664
Drug: Canagliflozin 150 mg
Normalized name: canagliflozin 150 MG
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
Study: NCT01340664
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
Study: NCT02202967
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
Study: NCT00755963
Drug: estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progynova® 21; 2mg/d
Study: NCT00755963
Drug: micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utrogestan®; 200mg/d
Study: NCT02342353
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02342353
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01230138
Drug: FP187
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High daily dose of 750mg administered as 250mg TID
Study: NCT01230138
Drug: FP187
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High daily dose of 750mg administered as 375mg BID
Study: NCT01230138
Drug: FP187
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Low daily dose of 500mg FP187 administered as 250mg BID
Study: NCT01230138
Drug: FP187
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablets, up to 3 times daily for 20 weeks.
Study: NCT02945163
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir Disoproxil Fumarate
Study: NCT02945163
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine
Study: NCT02945163
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz
Study: NCT03073863
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analysis
Study: NCT00153673
Drug: Dologesics
Normalized name: Dologesic
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dologesics 2 tablets bd
Study: NCT00690430
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
Study: NCT00690430
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
Study: NCT02194946
Drug: CM therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
Study: NCT02100930
Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor)
Normalized name: axatilimab-csfr
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01474785
Drug: human ghrelin
Normalized name: Human ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-1 pmol/kg.min of human ghrelin administered by IV two times
Study: NCT01964378
Drug: Cebranopadol
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
Study: NCT01964378
Drug: Morphine Prolonged Release
Normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
Study: NCT01619761
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01619761
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO